Chemical: Drug
mirtazapine

last updated 02/07/2014

1. DPWG Guideline for mirtazapine and CYP2D6

Summary

There are currently no dosing recommendations for mirtazapine based on CYP2D6 genotype.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2D6 genotype [Article:21412232]. They do not provide dosing recommendations at this time.

Phenotype (Genotype)Therapeutic Dose RecommendationLevel of EvidenceClinical Relevance
PM (2 inactive alleles)None.Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Clinical effect (S): short-lived discomfort (< 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia > 1.5x109/l; leucopenia > 3.0x109/l; thrombocytopenia > 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.
IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)None.Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Minor clinical effect (S): QTc prolongation (<450 ms men, <470 ms women); INR increase < 4.5. Kinetic effect (S).
UM (gene duplication in absence of inactive or decreased activity alleles)None.Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.Minor clinical effect (S): QTc prolongation (<450 ms men, <470 ms women); INR increase < 4.5. Kinetic effect (S).
Allele TypeAlleles
active*1, *2, *33, *35
decreased activity*9, *10, *17, *29, *36, *41
inactive*3-*8, *11-*16, *19-*21, *38, *40, *42
  • *See Methods or [Article:18253145] for definition of "moderate" quality.
  • S: statistically significant difference.


1. FDA Label for mirtazapine

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Depression
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depression, Postpartum
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depressive Disorder
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depressive Disorder, Major
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Hallucinations
    • Adverse reactions section
    • source: PHONT

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for mirtazapine

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available CYP2B6 *1 N/A N/A N/A
No VIP available CA No VIP available CYP2B6 *4 N/A N/A N/A
No VIP available CA No VIP available CYP2B6 *5 N/A N/A N/A
No VIP available CA VA CYP2B6 *6 N/A N/A N/A
No VIP available CA No VIP available CYP2B6 *7 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available CA VA CYP2D6 *1 N/A N/A N/A
No VIP available CA VA CYP2D6 *1xN N/A N/A N/A
No VIP available CA VA CYP2D6 *2xN N/A N/A N/A
No VIP available CA VA CYP2D6 *3 N/A N/A N/A
No VIP available CA VA CYP2D6 *4 N/A N/A N/A
No VIP available CA VA CYP2D6 *5 N/A N/A N/A
No VIP available CA VA CYP2D6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *41 N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR long form (L allele) N/A N/A N/A
No VIP available CA VA SLC6A4 HTTLPR short form (S allele) N/A N/A N/A
No VIP available CA No Variant Annotations available
rs10879346 NC_000012.11:g.72351835C>T, NC_000012.12:g.71958055C>T, NG_008279.1:g.24210C>T, NM_173353.3:c.608+8400C>T, XM_005268642.1:c.626+8400C>T, XM_011537899.1:c.14+8400C>T, XR_245894.1:n.613-3498C>T, XR_245894.2:n.709-3498C>T, rs59716601
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1360780 NC_000006.11:g.35607571T>C, NC_000006.12:g.35639794T>C, NG_012645.2:g.93790A>G, NM_001145775.2:c.106-2636A>G, NM_001145776.1:c.106-2636A>G, NM_001145777.1:c.106-2636A>G, NM_004117.3:c.106-2636A>G, XR_926743.1:n.287+5974T>C, rs58091271
T > C
SNP
No VIP available CA VA
rs1487278 NC_000012.11:g.72400851T>C, NC_000012.12:g.72007071T>C, NG_008279.1:g.73226T>C, NM_173353.3:c.1068+12506T>C, XM_005268642.1:c.1086+12506T>C, XM_011537899.1:c.474+12506T>C, rs61103738
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3800373 NC_000006.11:g.35542476C>A, NC_000006.12:g.35574699C>A, NG_012645.2:g.158885G>T, NM_001145775.2:c.*1136G>T, NM_001145776.1:c.*1136G>T, NM_004117.3:c.*1136G>T, XR_242006.1:n.180-18331C>A, XR_242006.2:n.433-18331C>A, XR_242008.1:n.201-18331C>A, rs386586584, rs60032290
C > A
SNP
No VIP available CA VA
rs4713916 NC_000006.11:g.35669983A>G, NC_000006.12:g.35702206A>G, NG_012645.2:g.31378T>C, NM_001145775.2:c.-20+18122T>C, rs17230143, rs35464630, rs9470083
A > G
SNP
No VIP available No Clinical Annotations available VA
rs6265 NC_000011.10:g.27658369C>T, NC_000011.9:g.27679916C>T, NG_011794.1:g.68690G>A, NM_001143805.1:c.196G>A, NM_001143806.1:c.196G>A, NM_001143807.1:c.196G>A, NM_001143808.1:c.196G>A, NM_001143809.1:c.283G>A, NM_001143810.1:c.442G>A, NM_001143811.1:c.196G>A, NM_001143812.1:c.196G>A, NM_001143813.1:c.196G>A, NM_001143814.1:c.196G>A, NM_001143816.1:c.196G>A, NM_001709.4:c.196G>A, NM_170731.4:c.220G>A, NM_170732.4:c.196G>A, NM_170733.3:c.196G>A, NM_170734.3:c.241G>A, NM_170735.5:c.196G>A, NP_001137277.1:p.Val66Met, NP_001137278.1:p.Val66Met, NP_001137279.1:p.Val66Met, NP_001137280.1:p.Val66Met, NP_001137281.1:p.Val95Met, NP_001137282.1:p.Val148Met, NP_001137283.1:p.Val66Met, NP_001137284.1:p.Val66Met, NP_001137285.1:p.Val66Met, NP_001137286.1:p.Val66Met, NP_001137288.1:p.Val66Met, NP_001700.2:p.Val66Met, NP_733927.1:p.Val74Met, NP_733928.1:p.Val66Met, NP_733929.1:p.Val66Met, NP_733930.1:p.Val81Met, NP_733931.1:p.Val66Met, NR_002832.2:n.503C>T, NR_033312.1:n.434C>T, NR_033313.1:n.434C>T, NR_033314.1:n.503C>T, NR_033315.1:n.434C>T, XM_005253060.1:c.442G>A, XM_011520280.1:c.442G>A, XP_005253117.1:p.Val148Met, XP_011518582.1:p.Val148Met, XR_242807.1:n.355C>T, XR_242808.1:n.352C>T, XR_242809.1:n.224-802C>T, rs16917222, rs17855547, rs3829232, rs386602118, rs60760775
C > -
C > A
SNP
V66M
No VIP available No Clinical Annotations available VA
rs6313 NC_000013.10:g.47469940G>A, NC_000013.11:g.46895805G>A, NG_013011.1:g.6230C>T, NM_000621.4:c.102C>T, NM_001165947.2:c.160+869C>T, NP_000612.1:p.Ser34=, rs17367493, rs3742280, rs386602276, rs57425741
G > A
SNP
S34S
No VIP available CA VA
rs948854 NC_000011.10:g.68682735C>T, NC_000011.9:g.68450203C>T, NM_015973.4:c.-1998C>T, rs59623113
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Mepirzepine
  • Mirtazapina [INN-Spanish]
  • Mirtazapine [Usan:Ban:Inn]
  • Mirtazapinum [INN-Latin]
  • Mirtazepine
  • mirtazapine
Trade Names
  • Avanza
  • Axit
  • Mirtabene
  • Mirtaz
  • Mirtazon
  • Norset
  • Promyrtil
  • Remergil
  • Remergon
  • Remeron
  • Remeron Soltab
  • Rexer
  • Zispin
Brand Mixture Names

PharmGKB Accession Id

PA450522

Type(s):

Drug

Description

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. Wikipedia

Source: Drug Bank

Indication

For the treatment of major depressive disorder.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Mirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT 1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT 1 receptors and as a potent antagonist at 5-HT 2 (particularly subtypes 2A and 2C) and 5-HT 3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.

Source: Drug Bank

Pharmacology

Mirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.

Source: Drug Bank

Food Interaction

Take without regard to meals. Avoid alcohol.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.

Source: Drug Bank

Protein Binding

85%

Source: Drug Bank

Absorption

Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.

Source: Drug Bank

Half-Life

20-40 hours

Source: Drug Bank

Toxicity

Symptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [Article:10333982]

Source: Drug Bank

Route of Elimination

This drug is known to be substantially excreted by the kidney (75%).

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H19N3

Source: Drug Bank

Isomeric SMILES

CN1CCN2c3c(cccn3)Cc4ccccc4C2C1

Source: OpenEye

Canonical SMILES

CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1

Source: Drug Bank

Average Molecular Weight

265.3529

Source: Drug Bank

Monoisotopic Molecular Weight

265.157897623

Source: Drug Bank

SMILES

CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA2A (source: Drug Bank)
HRH1 (source: Drug Bank)
HTR1A (source: Drug Bank)
HTR2A (source: Drug Bank)
HTR2C (source: Drug Bank)
HTR3A (source: Drug Bank)
OPRK1 (source: Drug Bank)

Drug Interactions

Interaction Description
clonidine - mirtazapine Possible hypertensive crisis (source: Drug Bank)
clonidine - mirtazapine Possible hypertensive crisis (source: Drug Bank)
donepezil - mirtazapine Possible antagonism of action (source: Drug Bank)
donepezil - mirtazapine Possible antagonism of action (source: Drug Bank)
fosphenytoin - mirtazapine The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
galantamine - mirtazapine Possible antagonism of action (source: Drug Bank)
galantamine - mirtazapine Possible antagonism of action (source: Drug Bank)
isocarboxazid - mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid - mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - clonidine Possible hypertensive crisis (source: Drug Bank)
mirtazapine - clonidine Possible hypertensive crisis (source: Drug Bank)
mirtazapine - donepezil Possible antagonism of action (source: Drug Bank)
mirtazapine - donepezil Possible antagonism of action (source: Drug Bank)
mirtazapine - ethotoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - fluvoxamine Fluvoxamine increases the effect and toxicity of mirtazapine (source: Drug Bank)
mirtazapine - fluvoxamine Fluvoxamine increases the effect and toxicity of mirtazapine (source: Drug Bank)
mirtazapine - fosphenytoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - galantamine Possible antagonism of action (source: Drug Bank)
mirtazapine - galantamine Possible antagonism of action (source: Drug Bank)
mirtazapine - isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - mephenytoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - mephenytoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - phenytoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - phenytoin The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
mirtazapine - rasagiline Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - rivastigmine Possible antagonism of action (source: Drug Bank)
mirtazapine - rivastigmine Possible antagonism of action (source: Drug Bank)
mirtazapine - tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
mirtazapine - tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
phenelzine - mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
phenelzine - mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
phenytoin - mirtazapine The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
phenytoin - mirtazapine The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects (source: Drug Bank)
rasagiline - mirtazapine Possible severe adverse reaction with this combination (source: Drug Bank)
telithromycin - mirtazapine Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
tramadol - mirtazapine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
tranylcypromine - mirtazapine The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Mirtazapine. These agents should not be administered within 14 days of each other. (source: Drug Bank)
trazodone - mirtazapine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
trazodone - mirtazapine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
trimipramine - mirtazapine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
triprolidine - mirtazapine The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
triprolidine - mirtazapine The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
venlafaxine - mirtazapine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
voriconazole - mirtazapine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)
zolmitriptan - mirtazapine Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to mirtazapine: 27

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenetics and genomics. 2013. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. The pharmacogenomics journal. 2013. Brandl E J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression. Journal of clinical psychopharmacology. 2012. Sirot Eveline Jaquenoud, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neuroscience letters. 2010. Zou Yan-Feng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New onset multimodal hallucinations associated with mirtazapine: a case report. International psychogeriatrics / IPA. 2010. Padala Kalpana P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Unschuld Paul G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2010. Oliver Paloma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FKBP5 polymorphisms and antidepressant response in geriatric depression. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2010. Sarginson Jane E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacological research : the official journal of the Italian Pharmacological Society. 2009. Borobia Alberto M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clinical pharmacokinetics. 2009. Lind Anna-Britta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug target identification using side-effect similarity. Science (New York, N.Y.). 2008. Campillos Monica, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenetics and genomics. 2008. Tzvetkov Mladen Vassilev, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biological psychiatry. 2008. Lekman Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in neuro-psychopharmacology & biological psychiatry. 2007. Tadi¿ André, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clinical pharmacology and therapeutics. 2007. Brockmöller J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. The pharmacogenomics journal. 2007. Kirchheiner J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. Pharmacogenomics. 2006. Popp Johannes, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. Journal of clinical psychopharmacology. 2004. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature genetics. 2004. Binder Elisabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of general psychiatry. 2004. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. European journal of clinical pharmacology. 2004. Kawanishi Chiaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of antidepressant medication intolerance. The American journal of psychiatry. 2003. Murphy Greer M, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0185-0020-30
DrugBank:
DB00370
ChEBI:
6950
KEGG Compound:
C07570
KEGG Drug:
D00563
PubChem Compound:
4205
PubChem Substance:
183976
46506965
Drugs Product Database (DPD):
2256126
ChemSpider:
4060
Therapeutic Targets Database:
DAP000010
FDA Drug Label at DailyMed:
b8df747e-dfce-4411-b892-086532ffabfb

Clinical Trials

These are trials that mention mirtazapine and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.